BIIB Biogen
- 190.520
- -1.640-0.85%
- 191.230
- +0.710+0.37%
Biogen News
UBS: Maintaining the Biogen (BIIB.US) rating, adjusted from neutral to neutral, and adjusted the target price from $250.00 to $214.00.
Wedbush: Maintaining the Biogen (BIIB.US) rating, adjusted from neutral to neutral, and adjusted the target price from $245.00 to $213.00.
Biogen Analyst Ratings
Biogen Analyst Ratings
B of A Securities: Maintaining the Biogen (BIIB.US) rating, adjusted from neutral to neutral, and adjusted the target price from $280.00 to $260.00.
Komo: Maintaining the Biogen (BIIB.US) rating, adjusted from neutral to neutral, and adjusted the target price from $270.00 to $240.00.
Biogen Analyst Ratings
JP Morgan Maintains Neutral on Biogen, Lowers Price Target to $240
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), KalVista Pharmaceuticals (KALV) and PTC Therapeutics (PTCT)
Morgan Stanley Trims Price Target on Biogen to $339 From $346, Keeps Overweight Rating
Barclays Cuts Price Target on Biogen to $215 From $230, Maintains Equalweight Rating
Biogen Analyst Ratings
Buy Rating on Biogen: Focused on Leqembi's IV Dosing Amidst SQ Formulation Delay
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Biogen (BIIB)
Hold Rating on Biogen Amidst Leqembi's Regulatory Challenges and Competitive Pressures
Analysts Offer Insights on Healthcare Companies: Aprea Therapeutics (APRE), Biogen (BIIB) and Mesoblast Limited (OtherMEOBF)
Biogen Analyst Ratings
Truist Securities Reiterates Buy on Biogen, Maintains $340 Price Target
Truist Financial Reaffirms Their Buy Rating on Biogen (BIIB)
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Biogen (BIIB)
Analysis
Price Target
No Data
